Category: Cardiac Rhythm Management
Medtronic says it won pre-market approval from the FDA for another pair of Attain Performa quadripolar cardiac resynchronization therapy defibrillator leads.
St. Jude Medical says it won CE Mark approval in the European Union for its Quadra Allure MP pacemaker, claiming it as the sole cardiac resynchronization therapy pacemaker to offer multi-point pacing.
A long-term study of data from registries set up by St. Jude Medical for its Optim-insulated defibrillator leads shows that they're largely free of the externalized conductor problem that plagued their Riata predecessors.
The FDA assigns Class I recall status to several lines of ConMed's defibrillator electrodes because they won't function with a number of updated devices made by Philips.
Iowa Approach says it landed an investment from Boston Scientific for the ablation device it's developing to treat atrial fibrillation.
Meta-analyses of Medtronic-sponsored studies show the clinical and economic benefits of its cardiac resynchronization therapy devices.
Medtronic (NYSE:MDT) yesterday touted the results of meta-analyses of a group of company-sponsored studies of its cardiac resynchronization therapy devices, saying the data show the clinical and economic value its CRT portfolio.
A Medtronic study shows hemodialysis patients experience significantly higher-than-expected rates of arrhythmia and that the episodes appeared to coincide with their treatment cycles.